Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
JAK inhibition in the treatment of diabetic kidney disease.
Authors
Brosius FC, Tuttle KR, Kretzler M
Submitted By
Matthias Kretzler on 7/13/2016
Status
Published
Journal
Diabetologia
Year
2016
Date Published
Volume : Pages
59 : 1624 - 7
PubMed Reference
27333885
Abstract
Diabetic kidney disease (DKD) is the most common cause of kidney failure in many
countries today, but treatments have not improved in the last 20 years.
Recently, systems biology methods have allowed the elucidation of signalling
pathways and networks involved in the progression of DKD that were not well
appreciated previously. A prominent pathway found to be integrally associated
with DKD progression is the Janus kinase-signal transducer and activator of
transcription (JAK-STAT) pathway. Increased expression of JAK-STAT genes was
found in multiple cells in the kidney, including glomerular podocytes, in both
early and progressive DKD. Subsequent experiments in a mouse diabetic model
showed that enhanced expression of JAK2 selectively in glomerular podocytes
increased functional and pathological features of DKD. Finally, a yet
unpublished Phase 2 multicentre, randomised, double-blind, placebo-controlled
study of the efficacy of a selective JAK1 and JAK2 inhibitor has been conducted
in type 2 diabetic participants with DKD. In this trial there was a reduction of
albuminuria in participants who received the active inhibitor compared with
those who received a placebo These results support the further study of JAK
inhibitors as a new therapy for DKD. This review summarises a presentation given
at the 'Anti-inflammatory interventions in diabetes' symposium at the 2015
annual meeting of the EASD. It is accompanied by an overview by the Session
Chair, Hiddo Heerspink (DOI: 10.1007/s00125-016-4030-4 ).
Investigators with authorship
Name
Institution
Frank Brosius
University of Arizona
Matthias Kretzler
University of Michigan
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!